SAFE-T is working to address the current lack of sensitive and specific clinical tests to diagnose and monitor drug-induced injury to the kidney, liver and vascular systems in man, which is a major hurdle in drug development.
Therefore, many promising candidate drugs with pre-clinical kidney, liver or vascular toxicity signals of unknown relevance do not enter the clinical phase, as no sensitive tests exist to allow timely detection of patient safety signs before irreversible injury occurs. New tests based on biomarkers will enable studies to assess whether these drugs are safe to ‘translate’ into clinical use. Furthermore, the new translational safety biomarkers will allow the identification and management of side effects of drugs throughout drug development helping to reduce the risk of developing medicines and improving the safety management of patients.
SAFE-T work generally falls under the goal of creating methods to enable personalised medicines that improve public health.